AU Patent

AU2012299177A1 — Combination cancer therapy of HSP90 inhibitor with antimetabolite

Assigned to Synta Phamaceuticals Corp · Expires 2014-04-10 · 12y expired

What this patent protects

The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formula…

USPTO Abstract

The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (I) or (la) in combination with an antimetabolite such as methotrexate, pemetrexed, cytarabine or nelarabine, or 5-fluorouracil, or capecitabine or their derivatives.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012299177A1
Jurisdiction
AU
Classification
—
Expires
2014-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Synta Phamaceuticals Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.